CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Jilin FuKang Medical and Biotech Co Ltd is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Jilin FuKang Medical and Biotech Co Ltd
No. 3 Huarui Road
Economic Development Zone, Dunhua City
Phone: +86 4336342079p:+86 4336342079 YANBIAN, JLN  133700  China Fax: +86 4336342159f:+86 4336342159

Business Summary
Jilin FuKang Medical Biotech Co., Ltd. is a China-based company mainly engaged in the manufacture and sales of Chinese medicine (including Chinese herbal medicine), chemicals products, health food and other food. Its main products include Chinese medicine and health food, in tablets and capsules. The Company's mainly market its products to commercial pharmaceutical companies or dealers.
(Source: PROSPECTUS)

Scores and Ratings
FRISK®
Score
Z''
Score
PAYCE®
Score
DBT
Index
Moody's
Rating
Fitch
Rating
DBRS
Rating
-Yes-----

Financials, News and Filings
Latest
Statement
Last
Audit

News
SEC
Filings
Bankruptcy
Filings
Suit &
Judgment
Filings
Tax
Lien
Filings
12/31/201512/31/2013Yes----

General Information
Fax Number: +86 4336342159


Copyright © 2023 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Saturday, October 21, 2023